Study S000652

A Multicenter, Randomized, Open, Parallel Controlled Phase III Study Comparing the Efficacy and Safety of Semaglutide Injection and Wegovy® for Weight Management in Obese Subjects

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT06738979
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: NONE
Status: COMPLETED
Enrollment: 408
Start: 2025-03-20
Primary completion: 2026-03-07
Lead sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions: Obesity
Interventions: DRUG:TQF3510 (Semaglutide Injection); DRUG:Wegovy®
Results posted: FALSE

Registered primary outcomes

Percentage (%) of body weight loss [Baseline to week 44]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.